Adverse reactions in long-term interferon treatment

Area of Science:

• Oncology
• Pharmacology
• Immunotherapy

Background:

• Interferon therapy is utilized for metastatic renal cell carcinoma.
• Long-term treatment schedules require evaluation for adverse reactions.
• Understanding side effects is crucial for patient management.

Purpose of the Study:

• To assess adverse reactions associated with long-term interferon-2b treatment in metastatic renal cell carcinoma.
• To compare side effect profiles between daily and thrice-weekly interferon administration.

Main Methods:

• A study involving thirteen patients with metastatic renal cell carcinoma receiving daily subcutaneous interferon-2b (10(7) units) for six months.
• A separate cohort of eleven patients received interferon-2b subcutaneously three times weekly as adjunctive therapy.
• Monitoring of general condition and weight changes was conducted.

Main Results:

• Daily interferon treatment led to serious side effects in ten of thirteen patients, including worsened general condition and an average weight loss of 7 kg.
• Remissions (1 complete, 2 partial) were observed after 2-3 months of daily treatment.
• Adjunctive, thrice-weekly interferon therapy was generally well-tolerated, with less severe side effects and mild weight loss in only one patient.

Conclusions:

• Daily long-term interferon-2b administration for metastatic renal cell carcinoma is associated with significant adverse events.
• Adjunctive, less frequent interferon therapy demonstrates improved tolerability.
• Dosage and schedule adjustments may be necessary to mitigate side effects in interferon treatment.